Announcements Trials
Browse Landscape

Phase

Phase 3 3Phase 2 2Phase 1/2 2Phase 1 2

Status

Recruiting 1Completed 1

Sponsor Class

OTHER 8INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other solid neoplasm 1Gastrointestinal 1

Conditions

Pancreatic Neoplasms 1Neoplasm Metastasis 1Locally Advanced Unresectable or Metastatic Solid Tumors 1Carcinoma 1Adenocarcinoma 1

Interventions

pembrolizumab 304Paclitaxel 206Carboplatin 200Gemcitabine 173Cisplatin 139Docetaxel 138Cyclophosphamide 136Nivolumab 129Bevacizumab 118Injections 111fludarabine 96atezolizumab 91Pemetrexed 90Dexamethasone 90Cetuximab 90Fluorouracil 84Irinotecan 77Rituximab 72Capecitabine 72venetoclax 71Azacitidine 70130-nm albumin-bound paclitaxel 67Leucovorin 65Fulvestrant 58Oxaliplatin 57durvalumab 56Trastuzumab 56Lenalidomide 55Ipilimumab 55Midazolam 54

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × INDUSTRY × folfirinox × Clear all
NCT05458219 2026-05-04

A First-in-human Study of IBI343 in Subjects With Locally Advanced Unresectable or Metastatic Solid Tumors

Innovent Biologics (Suzhou) Co. Ltd.

Phase 1 Recruiting
470 enrolled
Other solid neoplasm

Locally Advanced Unresectable or Metastatic Solid Tumors

NCT04990037 2023-06-29

CAPAFOUR

Cantargia AB

Phase 1 Completed
25 enrolled
Gastrointestinal

Adenocarcinoma, Carcinoma, Neoplasm Metastasis, Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡